You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 14, 2024

ENDO OPERATIONS Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ENDO OPERATIONS, and when can generic versions of ENDO OPERATIONS drugs launch?

ENDO OPERATIONS has two hundred and twenty-one approved drugs.

There are forty-one US patents protecting ENDO OPERATIONS drugs. There is one tentative approval on ENDO OPERATIONS drugs.

There are one hundred and nineteen patent family members on ENDO OPERATIONS drugs in forty countries and three hundred and fifty-three supplementary protection certificates in seventeen countries.

Summary for ENDO OPERATIONS
International Patents:119
US Patents:41
Tradenames:176
Ingredients:155
NDAs:221

Drugs and US Patents for ENDO OPERATIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride TABLET;ORAL 203836-001 Aug 19, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up
Endo Operations QUETIAPINE FUMARATE quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 090482-002 May 9, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up
Endo Operations LAMOTRIGINE lamotrigine TABLET, EXTENDED RELEASE;ORAL 201374-002 Dec 26, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up
Endo Operations LAMOTRIGINE lamotrigine TABLET, EXTENDED RELEASE;ORAL 201374-004 Dec 26, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up
Endo Operations SODIUM PHENYLBUTYRATE sodium phenylbutyrate TABLET;ORAL 204395-001 Apr 15, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up
Endo Operations OXYCODONE AND ACETAMINOPHEN acetaminophen; oxycodone hydrochloride TABLET;ORAL 040105-001 Jul 30, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ENDO OPERATIONS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Operations FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 6,319,913 ⤷  Sign Up
Endo Operations OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 8,329,216 ⤷  Sign Up
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 8,118,771 ⤷  Sign Up
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 5,891,086 ⤷  Sign Up
Endo Operations OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 5,662,933 ⤷  Sign Up
Endo Operations OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-007 Feb 29, 2008 5,128,143 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ENDO OPERATIONS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 20 units/mL, 1 mL ➤ Subscribe 2018-03-23
➤ Subscribe Extended-release Tablets 7.5 mg and 15 mg ➤ Subscribe 2008-05-29
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2011-03-09
➤ Subscribe Nasal Spray 500 mcg/spray ➤ Subscribe 2017-04-28
➤ Subscribe Gel 1% ➤ Subscribe 2008-08-21
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Injection 1 mg/mL ampules ➤ Subscribe 2016-03-09
➤ Subscribe Extended-release Tablets 5 mg, 10 mg, 20 mg and 40 mg ➤ Subscribe 2007-11-23
➤ Subscribe Extended-release Tablets 30 mg ➤ Subscribe 2008-06-12
➤ Subscribe Gel 10 mg/actuation ➤ Subscribe 2012-08-14
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe Injection 250 mg/mL ➤ Subscribe 2014-06-11
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01

Supplementary Protection Certificates for ENDO OPERATIONS Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2380576 SPC/GB20/050 United Kingdom ⤷  Sign Up PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; REGISTERED: UK PL 45496/0009 20170526
3342411 122020000008 Germany ⤷  Sign Up PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: EU/1/09/538/001-008 20110824
1441735 2008/010 Ireland ⤷  Sign Up PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
0268956 SPC/GB98/040 United Kingdom ⤷  Sign Up PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
2269604 132016000127697 Italy ⤷  Sign Up PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/538/001-006, 20090805
3143995 34/2019 Austria ⤷  Sign Up PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538 IDF DER ENTSCHEIDUNG DER KOMMISSION C (2016) 3286 (MITTEILUNG) 20160530
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.